Glioma clinical trials in Arizona
8 studies for Glioma are looking for participants at sites in Arizona.
Cities in Arizona
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
- Banner Children's at Desert, Mesa
RecruitingPhase 1/2
12 Months – 21 Years · All sexes · Updated Oct 1, 2026 · NCT05099003Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial
- Mayo Clinic in Arizona, Phoenix
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT05030298SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Mayo Clinic - Arizona, Phoenix
- St. Joseph's Hospital and Medical Center, Phoenix
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT05303519Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
- Honor Health, Scottsdale
Recruiting
Ages 18 to 85 · All sexes · Updated Jul 21, 2026 · NCT06910306Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Mayo Clinic Scottsdale, Scottsdale
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 13, 2026 · NCT06810544Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
- Mayo Clinic in Arizona, Phoenix
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Mar 24, 2026 · NCT06482905Mapping of Electrical Properties in the Brain
- Mayo Clinic in Arizona, Scottsdale
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Feb 3, 2026 · NCT06470711A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions
- Chandler Regional Medical Center, Chandler
- St. Joseph's Hospital and Medical Center, Phoenix
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Nov 20, 2025 · NCT06072586From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.